Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") announced today that it has completed an amendment to the securities purchase agreement (the "Amendment") with investment funds...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") announced today that veteran pharmaceutical industry executive Robert D. Tessarolo has been appointed President and Chief...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and 12 months ended December 31, 2016. Unless otherwise noted,...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it will host a conference call its Q4 and full-year 2016 financial results on Thursday, March 2, 2017. Q4 AND YEAR-END 2016 CONFERENCE CALL...

Cipher Pharmaceuticals Inc. (TSX:CPH; NASDAQ:CPHR) ("Cipher" or "the Company") today announced that its Board of Directors has approved the voluntary withdrawal of its common shares from NASDAQ...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended September 30, 2016. Unless otherwise...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Stephen L. Lemieux, Chief Financial Officer and Secretary of the Company, has been named Interim...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in response to a request for comment from Investment Industry Regulatory Organization of Canada ("IIROC") and an...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q3 2016 financial results on Friday, November 11, 2016. Q3 2016 CONFERENCE CALL WHEN:...

Company also announces appointment of Dr. John Mull as Chair of the Board of Directors MISSISSAUGA, ON, Sept. 1, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended June 30, 2016. Unless otherwise...

Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher") today announced certain changes to its board of directors (the "Board"). As previously disclosed, a special committee of the Board...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced preliminary estimates of its financial results for the three months ended June 30, 2016. The complete...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q2 2016 financial results on Wednesday, August 10, 2016. Q2 2016 CONFERENCE CALL WHEN:...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that its New Drug Submission for Ozenoxacin has been accepted for review by Health Canada. Ozenoxacin...

A special committee (the "Special Committee") of the board of directors (the "Board") of Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher") responded today to an Early Warning Report...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Edesa Biotech Inc. ("Edesa") has licensed the rights to ASF-1096 (R-salbutamol) for use in...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at two upcoming...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special...

- Revenue increased 23% - Delivered on multiple commercial and regulatory milestones - Positive cash from operating activities of $1.4 million while investing in future growth MISSISSAUGA, ON, May...

Product candidate may have the potential to transform tattoo removal process MISSISSAUGA, ON, May 2, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company")...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2016 financial results conference call and Annual and Special Meeting of...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Norm Evans, Chief Financial Officer, will be retiring from the Company. Mr. Evans will remain in...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two pharmaceutical industry leaders, are...

Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has received Health Canada approvals for SD Cream and AD Cream (also known as Dermadexin and...